Reduction in the Blood Pressures of Renal Hypertensive Dogs With Hog Renin

Wakerlin, G. E.; Johnson, Clarence A.; Gomberg, Bryon R.; Goldberg, Marvin

doi:10.1126/science.93.2414.332

Cited by 9 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of safety, there were no serious adverse events directly related to the therapy; however, local skin reactions at the injection site and low-grade fever were observed [13]. Around the same time, another group also demonstrated that daily intramuscular injection of pig renin for two months decreased blood pressure in hypertensive dogs, from an average femoral blood pressure of 164 mmHg to 114 mmHg, without any adverse events [14]. These findings showed the antihypertensive properties of heterologous renin (i.e., renin vaccine) and marked a great advance in the treatment of hypertension.…”

Section: Renin Vaccinesmentioning

confidence: 99%

Vaccine Development against the Renin-Angiotensin System for the Treatment of Hypertension

Azegami

Itoh

2019

International Journal of Hypertension

View full text Add to dashboard Cite

Hypertension is a global public health issue and the most important preventable cause of cardiovascular diseases. Despite the clinical availability of many antihypertensive drugs, many hypertensive patients have poor medication adherence and blood pressure control due, at least partially, to the asymptomatic and chronic characteristics of hypertension. Immunotherapeutic approaches have the potential to improve medication adherence in hypertension because they induce prolonged therapeutic effects and need a low frequency of administration. The first attempts to reduce blood pressure by using vaccines targeting the renin-angiotensin system were made more than half a century ago; however, at the time, a poor understanding of immunology and the mechanisms of hypertension and a lack of optimal vaccine technologies such as suitable antigen design, proper adjuvants, and effective antigen delivery systems meant that attempts to develop antihypertensive vaccines failed. Recent advances in immunology and vaccinology have provided potential therapeutic immunologic approaches to treat not only infectious diseases but also cancers and other noncommunicable diseases. One important biotechnology that has had a major impact on modern vaccinology is virus-like particle technology, which can efficiently deliver vaccine antigens without the need for artificial adjuvants. A human clinical trial that indicated the effectiveness and safety of a virus-like particle-based antiangiotensin II vaccine marked a turning point in the field of therapeutic antihypertensive vaccines. Here, we review the history of the development of immunotherapies for the treatment of hypertension and discuss the current perspectives in the field.

show abstract

Section: Renin Vaccinesmentioning

confidence: 99%

Vaccine Development against the Renin-Angiotensin System for the Treatment of Hypertension

Azegami

Itoh

2019

International Journal of Hypertension

View full text Add to dashboard Cite

show abstract

“…As an initiator of RAAS, renin plays an important part in hypertension. Since 1941, renin has been tested as a target to elicit immunity and to lower blood pressure [ 78 ]. However, early attempts to reduce blood pressure by vaccines against renin failed because of nephritis due to autoimmune issues [ 79 ].…”

Section: Introductionmentioning

confidence: 99%

Recent Advances in the Development of Vaccines for Diabetes, Hypertension, and Atherosclerosis

Meng

2018

Journal of Diabetes Research

View full text Add to dashboard Cite

Vaccines are commonly used in the prevention of infectious diseases. The basic principle of vaccination is to use specific antigens, endogenous or exogenous to stimulate immunity against the specific antigens or cells producing them. Autoantigen or oligo vaccination has been used for disease animal models. More recently humanized monoclonal antibodies have been successfully used for the treatment of neoplastic disorders or familial hypercholesterolemia. Humanized monoclonal antibody therapy needs repeated injection, and the therapy is expensive. Therapeutic vaccination can lead to persistent immunized or immune tolerant against the therapeutic molecule(s) or site. However, immunization against those endogenous substances may also elicit persistent autoimmune reaction or destruction that do harm to health. Therefore, rigorous studies are needed before any clinical application. In this review, we briefly reviewed vaccines used in protection against common metabolic diseases including atherosclerosis, hypertension, and diabetes mellitus.

show abstract

“…11 He was keenly interested in the immunologic approach of Wakerlin and Johnson 12 to the treatment of hypertension with crude renin, and began to purify the enzyme for his own studies of antirenin. The first extensive purification of renin was done by Lamfrom, Haas and Goldblatt in 1953.…”

mentioning

confidence: 99%

The Goldblatt memorial lecture. Part I: Experimental renovascular hyptertension.

Barger¹

1979

Hypertension

View full text Add to dashboard Cite

Reduction in the Blood Pressures of Renal Hypertensive Dogs With Hog Renin

Cited by 9 publications

References 2 publications

Vaccine Development against the Renin-Angiotensin System for the Treatment of Hypertension

Vaccine Development against the Renin-Angiotensin System for the Treatment of Hypertension

Recent Advances in the Development of Vaccines for Diabetes, Hypertension, and Atherosclerosis

The Goldblatt memorial lecture. Part I: Experimental renovascular hyptertension.

Contact Info

Product

Resources

About